| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 35 | 2024 | 97 | 14.260 |
Why?
|
| Aortic Valve Stenosis | 31 | 2024 | 170 | 11.540 |
Why?
|
| Percutaneous Coronary Intervention | 22 | 2024 | 169 | 7.950 |
Why?
|
| Atrial Appendage | 10 | 2024 | 28 | 5.980 |
Why?
|
| Treatment Outcome | 81 | 2025 | 5183 | 5.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 12 | 2024 | 154 | 5.160 |
Why?
|
| Heart Valve Prosthesis | 11 | 2023 | 90 | 4.680 |
Why?
|
| Myocardial Infarction | 21 | 2024 | 864 | 4.520 |
Why?
|
| Aortic Valve | 20 | 2024 | 168 | 3.960 |
Why?
|
| Cardiac Catheterization | 10 | 2024 | 250 | 3.660 |
Why?
|
| ST Elevation Myocardial Infarction | 12 | 2024 | 76 | 3.460 |
Why?
|
| Atrial Fibrillation | 12 | 2024 | 798 | 3.240 |
Why?
|
| Stroke | 14 | 2024 | 1138 | 3.240 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2024 | 252 | 2.490 |
Why?
|
| Embolism | 4 | 2024 | 38 | 2.460 |
Why?
|
| Heart-Assist Devices | 9 | 2023 | 126 | 2.460 |
Why?
|
| Humans | 123 | 2025 | 59517 | 2.340 |
Why?
|
| Pulmonary Embolism | 4 | 2024 | 170 | 2.330 |
Why?
|
| Shock, Cardiogenic | 12 | 2024 | 85 | 2.240 |
Why?
|
| Acute Coronary Syndrome | 4 | 2024 | 258 | 2.200 |
Why?
|
| Risk Factors | 36 | 2025 | 5016 | 2.120 |
Why?
|
| Femoral Artery | 4 | 2022 | 93 | 2.020 |
Why?
|
| Thrombosis | 5 | 2023 | 195 | 1.990 |
Why?
|
| Thrombolytic Therapy | 4 | 2024 | 181 | 1.870 |
Why?
|
| Anemia | 6 | 2024 | 117 | 1.870 |
Why?
|
| Peripheral Arterial Disease | 5 | 2020 | 155 | 1.850 |
Why?
|
| Foramen Ovale, Patent | 2 | 2024 | 13 | 1.810 |
Why?
|
| Hospital Mortality | 12 | 2025 | 846 | 1.770 |
Why?
|
| Hemorrhage | 7 | 2024 | 277 | 1.720 |
Why?
|
| Endocarditis | 3 | 2022 | 20 | 1.710 |
Why?
|
| Pacemaker, Artificial | 4 | 2022 | 42 | 1.710 |
Why?
|
| Ischemic Attack, Transient | 3 | 2024 | 90 | 1.700 |
Why?
|
| Coronary Artery Disease | 7 | 2024 | 277 | 1.690 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2024 | 94 | 1.670 |
Why?
|
| Mitral Valve | 3 | 2023 | 104 | 1.650 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2023 | 41 | 1.570 |
Why?
|
| Retrospective Studies | 27 | 2025 | 6009 | 1.530 |
Why?
|
| Coronary Occlusion | 2 | 2021 | 7 | 1.390 |
Why?
|
| Bioprosthesis | 2 | 2022 | 39 | 1.350 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2025 | 669 | 1.320 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2023 | 249 | 1.270 |
Why?
|
| Aged | 37 | 2025 | 13341 | 1.270 |
Why?
|
| Ventricular Septal Rupture | 2 | 2019 | 2 | 1.260 |
Why?
|
| Radiation Exposure | 2 | 2019 | 15 | 1.230 |
Why?
|
| Patient Readmission | 9 | 2024 | 420 | 1.200 |
Why?
|
| Cardiology | 4 | 2024 | 165 | 1.190 |
Why?
|
| Endovascular Procedures | 5 | 2024 | 568 | 1.190 |
Why?
|
| Radiography, Interventional | 2 | 2019 | 70 | 1.180 |
Why?
|
| Databases, Factual | 9 | 2024 | 838 | 1.170 |
Why?
|
| Acute Kidney Injury | 5 | 2022 | 131 | 1.160 |
Why?
|
| Radiation Dosage | 2 | 2019 | 125 | 1.150 |
Why?
|
| Male | 41 | 2025 | 27572 | 1.070 |
Why?
|
| Time Factors | 19 | 2024 | 3579 | 1.060 |
Why?
|
| Thromboembolism | 2 | 2023 | 70 | 1.050 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 5089 | 1.040 |
Why?
|
| Postoperative Complications | 9 | 2024 | 1134 | 1.000 |
Why?
|
| Risk Assessment | 12 | 2024 | 1915 | 0.980 |
Why?
|
| Female | 41 | 2025 | 30918 | 0.980 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 53 | 0.950 |
Why?
|
| Fasting | 1 | 2024 | 51 | 0.950 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2024 | 35 | 0.900 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 330 | 0.900 |
Why?
|
| Atrial Flutter | 1 | 2024 | 20 | 0.890 |
Why?
|
| Vascular System Injuries | 1 | 2024 | 20 | 0.890 |
Why?
|
| Radial Artery | 2 | 2022 | 43 | 0.870 |
Why?
|
| Migraine Disorders | 1 | 2024 | 45 | 0.870 |
Why?
|
| Septal Occluder Device | 2 | 2024 | 11 | 0.850 |
Why?
|
| Drug Administration Schedule | 1 | 2023 | 282 | 0.850 |
Why?
|
| Calcinosis | 1 | 2023 | 79 | 0.840 |
Why?
|
| Social Media | 2 | 2024 | 112 | 0.840 |
Why?
|
| Fibrinolytic Agents | 5 | 2024 | 165 | 0.830 |
Why?
|
| United States | 23 | 2025 | 7513 | 0.820 |
Why?
|
| Heart Arrest | 1 | 2025 | 158 | 0.820 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2023 | 64 | 0.810 |
Why?
|
| Coronary Circulation | 2 | 2020 | 52 | 0.800 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 45 | 0.800 |
Why?
|
| Inventions | 1 | 2021 | 3 | 0.780 |
Why?
|
| Kidney | 2 | 2023 | 395 | 0.780 |
Why?
|
| Off-Label Use | 1 | 2021 | 15 | 0.780 |
Why?
|
| Endocarditis, Bacterial | 1 | 2022 | 30 | 0.770 |
Why?
|
| Balloon Valvuloplasty | 1 | 2021 | 9 | 0.770 |
Why?
|
| Reoperation | 2 | 2022 | 254 | 0.770 |
Why?
|
| Middle Aged | 23 | 2025 | 16276 | 0.760 |
Why?
|
| Blood Transfusion | 5 | 2024 | 148 | 0.750 |
Why?
|
| Mammary Arteries | 1 | 2020 | 11 | 0.730 |
Why?
|
| Lower Extremity | 2 | 2020 | 145 | 0.730 |
Why?
|
| Hospital Costs | 3 | 2020 | 120 | 0.720 |
Why?
|
| Choice Behavior | 1 | 2021 | 76 | 0.710 |
Why?
|
| Benchmarking | 1 | 2022 | 135 | 0.710 |
Why?
|
| Vascular Closure Devices | 1 | 2020 | 2 | 0.690 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2020 | 45 | 0.690 |
Why?
|
| Drug Costs | 1 | 2020 | 59 | 0.680 |
Why?
|
| Drug-Eluting Stents | 4 | 2024 | 54 | 0.670 |
Why?
|
| Intracranial Embolism | 1 | 2020 | 39 | 0.670 |
Why?
|
| Sex Factors | 4 | 2025 | 960 | 0.660 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 100 | 0.650 |
Why?
|
| Collateral Circulation | 1 | 2019 | 22 | 0.640 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 88 | 0.640 |
Why?
|
| Anticoagulants | 5 | 2024 | 487 | 0.630 |
Why?
|
| Arteries | 2 | 2020 | 75 | 0.630 |
Why?
|
| Ultrasonography, Interventional | 4 | 2024 | 91 | 0.630 |
Why?
|
| Contrast Media | 2 | 2024 | 410 | 0.630 |
Why?
|
| Vascular Surgical Procedures | 2 | 2024 | 245 | 0.620 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2018 | 8 | 0.620 |
Why?
|
| Echocardiography | 6 | 2024 | 459 | 0.600 |
Why?
|
| Equipment Failure | 1 | 2018 | 65 | 0.600 |
Why?
|
| Heart Failure | 5 | 2024 | 867 | 0.580 |
Why?
|
| Length of Stay | 7 | 2024 | 771 | 0.570 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 537 | 0.550 |
Why?
|
| Paclitaxel | 1 | 2017 | 90 | 0.550 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2017 | 209 | 0.520 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2025 | 750 | 0.510 |
Why?
|
| Skin Diseases, Genetic | 1 | 2015 | 7 | 0.490 |
Why?
|
| Vascular Malformations | 1 | 2015 | 20 | 0.480 |
Why?
|
| Joint Instability | 1 | 2015 | 40 | 0.480 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 279 | 0.460 |
Why?
|
| Catheters | 3 | 2023 | 67 | 0.460 |
Why?
|
| Cardiologists | 3 | 2024 | 25 | 0.460 |
Why?
|
| Chronic Disease | 4 | 2021 | 735 | 0.440 |
Why?
|
| Prosthesis Design | 5 | 2021 | 205 | 0.430 |
Why?
|
| Microcirculation | 3 | 2024 | 50 | 0.400 |
Why?
|
| Recovery of Function | 6 | 2024 | 261 | 0.400 |
Why?
|
| Ischemia | 3 | 2024 | 192 | 0.400 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 827 | 0.390 |
Why?
|
| Clinical Protocols | 2 | 2024 | 134 | 0.360 |
Why?
|
| Prospective Studies | 6 | 2024 | 3101 | 0.350 |
Why?
|
| Inpatients | 5 | 2023 | 296 | 0.340 |
Why?
|
| Patient Discharge | 4 | 2021 | 479 | 0.320 |
Why?
|
| Secondary Prevention | 2 | 2024 | 153 | 0.320 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2019 | 33 | 0.320 |
Why?
|
| Aspirin | 3 | 2022 | 186 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 715 | 0.310 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 114 | 0.310 |
Why?
|
| Operative Time | 2 | 2019 | 63 | 0.310 |
Why?
|
| Hospitalization | 3 | 2024 | 1283 | 0.300 |
Why?
|
| Equipment Design | 2 | 2020 | 317 | 0.300 |
Why?
|
| Registries | 3 | 2020 | 803 | 0.290 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 926 | 0.280 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2024 | 16 | 0.280 |
Why?
|
| Medicare | 3 | 2021 | 601 | 0.260 |
Why?
|
| Hospitals | 4 | 2024 | 376 | 0.260 |
Why?
|
| Coronary Angiography | 6 | 2023 | 172 | 0.260 |
Why?
|
| Prosthesis Failure | 2 | 2022 | 70 | 0.250 |
Why?
|
| Urea | 1 | 2025 | 34 | 0.240 |
Why?
|
| Respiratory Aspiration | 1 | 2024 | 6 | 0.240 |
Why?
|
| Cardiac Myosins | 1 | 2025 | 22 | 0.240 |
Why?
|
| Uracil | 1 | 2025 | 30 | 0.240 |
Why?
|
| Benzylamines | 1 | 2025 | 29 | 0.240 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2023 | 75 | 0.240 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 263 | 0.230 |
Why?
|
| Stroke Volume | 3 | 2023 | 318 | 0.230 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 13 | 0.230 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2024 | 55 | 0.220 |
Why?
|
| Adenosine Monophosphate | 1 | 2023 | 26 | 0.220 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2025 | 85 | 0.220 |
Why?
|
| Preoperative Care | 1 | 2024 | 176 | 0.220 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 23 | 0.220 |
Why?
|
| Limb Salvage | 1 | 2024 | 66 | 0.220 |
Why?
|
| Health Resources | 1 | 2024 | 88 | 0.220 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 60 | 0.220 |
Why?
|
| Conservative Treatment | 2 | 2022 | 13 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2024 | 130 | 0.210 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 141 | 0.210 |
Why?
|
| Lactates | 1 | 2022 | 28 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 149 | 0.200 |
Why?
|
| Disease Management | 1 | 2024 | 220 | 0.200 |
Why?
|
| Angiography | 4 | 2023 | 145 | 0.200 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 109 | 0.200 |
Why?
|
| Patient Selection | 1 | 2024 | 446 | 0.190 |
Why?
|
| Thrombectomy | 1 | 2023 | 205 | 0.190 |
Why?
|
| Atherectomy, Coronary | 1 | 2021 | 13 | 0.190 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 26 | 0.190 |
Why?
|
| Vascular Calcification | 1 | 2021 | 20 | 0.190 |
Why?
|
| Survival Rate | 3 | 2024 | 791 | 0.190 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 274 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2022 | 147 | 0.180 |
Why?
|
| Computer Simulation | 1 | 2023 | 455 | 0.180 |
Why?
|
| Subclavian Artery | 1 | 2020 | 24 | 0.180 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 82 | 0.180 |
Why?
|
| Prognosis | 3 | 2020 | 1572 | 0.180 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2020 | 32 | 0.180 |
Why?
|
| High-Energy Shock Waves | 1 | 2020 | 4 | 0.180 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 96 | 0.180 |
Why?
|
| Incidence | 3 | 2018 | 1237 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2020 | 41 | 0.170 |
Why?
|
| Seasons | 1 | 2020 | 130 | 0.170 |
Why?
|
| Stents | 2 | 2023 | 443 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 125 | 0.170 |
Why?
|
| Embolic Protection Devices | 1 | 2019 | 2 | 0.170 |
Why?
|
| Factor VIIa | 1 | 2019 | 4 | 0.170 |
Why?
|
| Mechanical Thrombolysis | 1 | 2020 | 35 | 0.170 |
Why?
|
| Prosthesis Implantation | 1 | 2020 | 30 | 0.170 |
Why?
|
| Punctures | 1 | 2020 | 53 | 0.170 |
Why?
|
| Brachiocephalic Trunk | 1 | 2019 | 15 | 0.170 |
Why?
|
| Hemophilia A | 1 | 2019 | 57 | 0.170 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2019 | 34 | 0.170 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 80 | 0.170 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2019 | 19 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1449 | 0.160 |
Why?
|
| Upper Extremity | 1 | 2019 | 49 | 0.160 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 63 | 0.160 |
Why?
|
| Hospitals, Teaching | 1 | 2019 | 103 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 422 | 0.160 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 27 | 0.160 |
Why?
|
| Intermittent Claudication | 1 | 2019 | 48 | 0.160 |
Why?
|
| Patient Admission | 1 | 2020 | 185 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 299 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2019 | 56 | 0.150 |
Why?
|
| Hemoglobins | 3 | 2024 | 139 | 0.150 |
Why?
|
| Porosity | 1 | 2018 | 38 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 31 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 160 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 436 | 0.150 |
Why?
|
| Prevalence | 2 | 2022 | 1281 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2019 | 164 | 0.150 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 117 | 0.150 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2017 | 19 | 0.150 |
Why?
|
| Radiation Protection | 1 | 2017 | 24 | 0.150 |
Why?
|
| Scattering, Radiation | 1 | 2017 | 72 | 0.150 |
Why?
|
| Aortography | 1 | 2017 | 54 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 220 | 0.140 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 21 | 0.140 |
Why?
|
| Atherectomy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Pseudoephedrine | 1 | 2017 | 1 | 0.140 |
Why?
|
| Popliteal Artery | 1 | 2017 | 25 | 0.140 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 36 | 0.140 |
Why?
|
| Nitroglycerin | 1 | 2017 | 12 | 0.140 |
Why?
|
| Metoprolol | 1 | 2017 | 11 | 0.140 |
Why?
|
| Coronary Vasospasm | 1 | 2017 | 11 | 0.140 |
Why?
|
| Curriculum | 1 | 2021 | 550 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 112 | 0.140 |
Why?
|
| Angioplasty, Balloon | 1 | 2017 | 57 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2017 | 69 | 0.130 |
Why?
|
| Logistic Models | 1 | 2019 | 1252 | 0.130 |
Why?
|
| Patient Safety | 1 | 2017 | 243 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 446 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2024 | 773 | 0.120 |
Why?
|
| Ticlopidine | 1 | 2014 | 66 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 2 | 2024 | 75 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 2442 | 0.110 |
Why?
|
| Asthma | 1 | 2017 | 420 | 0.100 |
Why?
|
| Microbubbles | 2 | 2024 | 2 | 0.100 |
Why?
|
| Electrocardiography | 3 | 2020 | 524 | 0.100 |
Why?
|
| Hemodynamics | 2 | 2019 | 236 | 0.070 |
Why?
|
| Access to Information | 1 | 2024 | 30 | 0.060 |
Why?
|
| Diffusion of Innovation | 1 | 2024 | 56 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2024 | 98 | 0.060 |
Why?
|
| Computer-Assisted Instruction | 1 | 2024 | 81 | 0.060 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 101 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 47 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2024 | 117 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 70 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2024 | 403 | 0.050 |
Why?
|
| Ankle Brachial Index | 1 | 2022 | 13 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 90 | 0.050 |
Why?
|
| Bundle-Branch Block | 1 | 2022 | 14 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 659 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2002 | 35 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2002 | 52 | 0.050 |
Why?
|
| Recurrence | 1 | 2023 | 578 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2022 | 152 | 0.050 |
Why?
|
| Warfarin | 1 | 2022 | 109 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 524 | 0.050 |
Why?
|
| Aftercare | 1 | 2021 | 67 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2023 | 330 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 420 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 112 | 0.040 |
Why?
|
| Friends | 1 | 2020 | 29 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 2040 | 0.040 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 24 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1518 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2022 | 201 | 0.040 |
Why?
|
| Adult | 3 | 2022 | 15787 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 630 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 95 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 102 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 741 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2019 | 134 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2019 | 133 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2019 | 33 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 221 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2020 | 251 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 355 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 276 | 0.040 |
Why?
|
| Emergencies | 1 | 2018 | 114 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2019 | 204 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 61 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 900 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 93 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2017 | 97 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2017 | 84 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2003 | 1457 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 1489 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1091 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1023 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2329 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 5932 | 0.020 |
Why?
|
| PAX6 Transcription Factor | 1 | 2003 | 4 | 0.010 |
Why?
|
| Paired Box Transcription Factors | 1 | 2003 | 17 | 0.010 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2003 | 16 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2003 | 23 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2003 | 70 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 148 | 0.010 |
Why?
|
| Eye Proteins | 1 | 2003 | 73 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 215 | 0.010 |
Why?
|
| Gestational Age | 1 | 2003 | 183 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 385 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 161 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 2002 | 56 | 0.010 |
Why?
|
| Crystallization | 1 | 2002 | 97 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 526 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 595 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 254 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2003 | 336 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1979 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 1989 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1470 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 1131 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 3195 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 10280 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 19661 | 0.000 |
Why?
|